{"nctId":"NCT00006164","briefTitle":"Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","startDateStruct":{"date":"2000-06","type":"ACTUAL"},"conditions":["Chronic Hepatitis c","Cirrhosis, Liver","Fibrosis, Liver","Hepatic Cirrhosis"],"count":1050,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Peginterferon alfa-2a + Ribavirin","Drug: Peginterferon alfa-2a"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Peginterferon alfa-2a + Ribavirin"]}],"interventions":[{"name":"Peginterferon alfa-2a + Ribavirin","otherNames":["Pegasys (Hoffman-La Roche)","Copegus (Hoffman-La Roche)"]},{"name":"Peginterferon alfa-2a","otherNames":["Pegasys (Hoffman-La Roche)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age at entry at least 18 years.\n* Positive for Hepatitis C.\n* Previous treatment with any interferon or interferon and ribavirin for at least 3 months.\n* Documented non-response to treatment with interferon.\n* A liver biopsy demonstrating significant liver scarring.\n\nExclusion Criteria:\n\n* No other liver disease.\n* No unstable major medical diseases or conditions.\n* No major complications of cirrhosis.\n* No recent abuse of alcohol or illicit drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points","description":"Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]},{"type":"PRIMARY","title":"Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies","description":"For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"PRIMARY","title":"Death From Any Cause","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Development of Hepatocellular Carcinoma (HCC)","description":"A diagnosis of development of hepatocellular carcinoma (HCC) was based on either\n\n1. Histology showing HCC (from a biopsy, surgery, or autopsy) or\n2. A new hepatic defect on imaging with an alpha-fetoproteion (AFP) level rising to \\> 1,000 ng/ml.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits","description":"Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"PRIMARY","title":"Variceal Hemorrhage","description":"A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Ascites","description":"Any abdominal fluid which is:\n\n1. Mild, moderate or marked on ultrasound; or\n2. Progressive on serial physical examinations; or\n3. Requires diuretic therapy. To meet the definition of ascites, abdominal fluid that is \"mild\" (\"barely detectable\") on physical examination requires ultrasound confirmation that is \"mild\", \"moderate\" or \"marked\" ascites. Ultrasound reports of minimal fluid around the liver do not meet the definition.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"PRIMARY","title":"Spontaneous Bacterial Peritonitis","description":"Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (\\> 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Hepatic Encephalopathy","description":"Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events","description":"A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:\n\n1. Death\n2. Is life threatening (risk of death at the time of the event)\n3. Requires in-patient hospitalization or prolongation of existing hospitalization\n4. Results in persistent or significant disability/incapacity\n5. Congenital abnormality or birth defect\n\nTrial outcomes (except death) were not considered serious adverse events.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.","description":"Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"1.27"},{"groupId":"OG001","value":"-0.09","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"1.36"},{"groupId":"OG001","value":"0.12","spread":"1.43"}]}]}]},{"type":"SECONDARY","title":"Presumed Hepatocellular Carcinoma (HCC)","description":"Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is \\<1000 ng/ml, if:\n\n1. A new hepatic lesion was shown on ultrasound and 1 additional imaging showed a hepatic lesion with characteristics of HCC.\n2. AFP\\> upper limit of normal (ULN) and 2 imaging studies showed a hepatic lesion with characteristics of HCC.\n3. A progressively enlarging hepatic lesion starting as a new defect resulting in patient death.\n4. A new hepatic defect with at least 1 characteristic scan and:\n\n   1. Increase in size over time or\n   2. Increasing AFP rising to a level of \\>200 ng/ml","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"SF-36 Vitality Summary Score","description":"Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.05","spread":"20.5"},{"groupId":"OG001","value":"-1.61","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.40","spread":"20.31"},{"groupId":"OG001","value":"-3.24","spread":"20.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.68","spread":"21.71"},{"groupId":"OG001","value":"-2.97","spread":"19.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.69","spread":"19.83"},{"groupId":"OG001","value":"-3.27","spread":"23.3"}]}]}]},{"type":"SECONDARY","title":"SF-36 Physical Function Summary Score","description":"Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.64","spread":"8.66"},{"groupId":"OG001","value":"-0.97","spread":"8.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"9.10"},{"groupId":"OG001","value":"-1.63","spread":"9.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.99","spread":"9.87"},{"groupId":"OG001","value":"-1.68","spread":"9.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.80","spread":"9.56"},{"groupId":"OG001","value":"-1.66","spread":"9.10"}]}]}]},{"type":"SECONDARY","title":"SF-36 Mental Health Summary Score","description":"Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":"9.58"},{"groupId":"OG001","value":"-1.08","spread":"9.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"9.68"},{"groupId":"OG001","value":"-1.67","spread":"9.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":"10.17"},{"groupId":"OG001","value":"-2.15","spread":"10.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.84","spread":"9.56"},{"groupId":"OG001","value":"-1.85","spread":"10.88"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":175,"n":517},"commonTop":["Abdominal pain","Muscle/back aches or pain","Fatigue, malaise, weakness","Arthralgia","Depression"]}}}